New!
Portfolio
Login
/
Sign Up
Search
Industries
Technology
Energy
Media
Finance
Green Issues
China
All Concepts
Metals
Energy
Meats
Grains
Softs
ETFs
Indices
Currencies
Geographies
Exchanges
Rates
How To Invest
Personal Finance
Options 101
Definitions
close
close
close
close
Send us Feedback
Chemed (CHE)
SUMMARY
BULLS
BEARS
TOPICS
DATA CENTRAL
STOCK CHART
SEC FILINGS
BALANCE
INCOME
CASH FLOW
Key Metrics for CHE as compared to
Top Competitors
Home Health Care
Pharma & Healthcare
All values TTM unless otherwise noted (*)
INCOME STATEMENT (
See all
)
Revenue
►
1.44B
EBITDA
►
209M
Net Income
►
91.1M
Revenue Growth
►
4.8%
Net Income Growth
►
3.2%
Operating Margin
►
11.2%
Net Margin
►
6.3%
Revenue, Net Income, and Net Margin
Revenue, Gross Profit, and Gross Margin
Operating Income
Ebit
Income Before Taxes
Net Income from Continuing Ops
Interest vs Continuing Income
Interest Coverage
Operating Expenses
Research & Development
SG&A
Amortization & Depreciation
Please install
Flash Player
to view this chart.
BALANCE SHEET (most recent quarter) (
See all
)
Debt / Equity
►
0.862
Current Ratio
►
1.47
Quick Ratio
►
1.43
Interest Coverage Ratio
►
10.8
Book Value Per Share
►
25.6
Cash Per Share
►
3.87
ASSETS
LIABILITIES
Cash
73.0M
Current Liabilities
161M
Other Current Assets
163M
Long-term Debt
177M
Fixed Assets
90.4M
Other Liabilities
78.4M
Other Assets
573M
Total Liabilities
416M
Total Assets
899M
Total Equity
483M
INDUSTRY METRICS (
See all
|
Compare across Pharma & Healthcare
)
Revenue
►
1.44B
Revenue
Net Income
Operating Income
SEC FILINGS (
See all
)
10-K (Feb 13)
Older:
02/27/12
,
02/27/12
,
02/28/11
,
02/26/10
10-Q (Apr 13)
Older:
11/02/12
,
11/02/12
,
08/02/12
,
08/02/12
8-K (May 13)
Older:
05/03/13
,
04/18/13
,
03/08/13
,
02/20/13
Form 4 (Apr 13)
Older:
04/26/13
,
04/24/13
,
04/24/13
,
03/01/13
View All Filings for Chemed (CHE)
STOCK SUMMARY
Open
Day Range
-
52 Week Range
-
Volume
Avg Volume (3 mo)
Shares Outstanding
18868108.00000
Market Cap
EPS
4.83
VALUATION
Price to Earnings (P/E)
►
14.0
Price to Book (P/B)
►
2.64
Price to Sales (P/S)
►
0.885
Return on Assets (ROA)
►
12.3%
Return on Equity (ROE)
►
19.9%
EV/EBITDA
►
6.46
Dividend Yield
1.1%
OWNERSHIP
Net Insider Buying 3mo
-0.8%
Net Insider Buying 6mo
-2%
Net Insider Buying 1yr
-12.4%
Held by insiders
4.3%
Held by institutions
104.9%
〉
〉
〉
〉
〉
〉
〉
〉
〉
〉
〉
〉
〉
〉
〉
〉
〉
〉
〉
〉
〉
〉
〉
〉
〉
〉
〉
〉
〉
〉
〉
〉
〉
〉
〉
Bet you've never seen portfolio analytics like these.
Introducing
SigFig
— from the creators of
Take Tour